Teva Pharmaceuticals has agreed to a $450 million settlement with the U.S. government to resolve allegations of violating the Anti-Kickback Statute and False Claims Act. The settlement stems from accusations that Teva engaged in two unlawful kickback schemes involving the multiple sclerosis drug Copaxone and price-fixing of generic drugs. This settlement is the largest among a series of cases targeting pharmaceutical companies for unlawfully paying patient copays through third-party foundations.